OBJECT: Accurate discrimination between tumor and normal tissue is crucial for optimal tumor resection. Qualitative fluorescence of protoporphyrin IX (PpIX), synthesized endogenously following δ-aminolevulinic acid (ALA) administration, has been used for this purpose in high-grade glioma (HGG). The authors show that diagnostically significant but visually imperceptible concentrations of PpIX can be quantitatively measured in vivo and used to discriminate normal from neoplastic brain tissue across a range of tumor histologies. METHODS: The authors studied 14 patients with diagnoses of low-grade glioma (LGG), HGG, meningioma, and metastasis under an institutional review board-approved protocol for fluorescence-guided resection. The primary aim of the study was to compare the diagnostic capabilities of a highly sensitive, spectrally resolved quantitative fluorescence approach to conventional fluorescence imaging for detection of neoplastic tissue in vivo. RESULTS: A significant difference in the quantitative measurements of PpIX concentration occurred in all tumor groups compared with normal brain tissue. Receiver operating characteristic (ROC) curve analysis of PpIX concentration as a diagnostic variable for detection of neoplastic tissue yielded a classification efficiency of 87% (AUC = 0.95, specificity = 92%, sensitivity = 84%) compared with 66% (AUC = 0.73, specificity = 100%, sensitivity = 47%) for conventional fluorescence imaging (p < 0.0001). More than 81% (57 of 70) of the quantitative fluorescence measurements that were below the threshold of the surgeon's visual perception were classified correctly in an analysis of all tumors. CONCLUSIONS: These findings are clinically profound because they demonstrate that ALA-induced PpIX is a targeting biomarker for a variety of intracranial tumors beyond HGGs. This study is the first to measure quantitative ALA-induced PpIX concentrations in vivo, and the results have broad implications for guidance during resection of intracranial tumors.
OBJECT: Accurate discrimination between tumor and normal tissue is crucial for optimal tumor resection. Qualitative fluorescence of protoporphyrin IX (PpIX), synthesized endogenously following δ-aminolevulinic acid (ALA) administration, has been used for this purpose in high-grade glioma (HGG). The authors show that diagnostically significant but visually imperceptible concentrations of PpIX can be quantitatively measured in vivo and used to discriminate normal from neoplastic brain tissue across a range of tumor histologies. METHODS: The authors studied 14 patients with diagnoses of low-grade glioma (LGG), HGG, meningioma, and metastasis under an institutional review board-approved protocol for fluorescence-guided resection. The primary aim of the study was to compare the diagnostic capabilities of a highly sensitive, spectrally resolved quantitative fluorescence approach to conventional fluorescence imaging for detection of neoplastic tissue in vivo. RESULTS: A significant difference in the quantitative measurements of PpIX concentration occurred in all tumor groups compared with normal brain tissue. Receiver operating characteristic (ROC) curve analysis of PpIX concentration as a diagnostic variable for detection of neoplastic tissue yielded a classification efficiency of 87% (AUC = 0.95, specificity = 92%, sensitivity = 84%) compared with 66% (AUC = 0.73, specificity = 100%, sensitivity = 47%) for conventional fluorescence imaging (p < 0.0001). More than 81% (57 of 70) of the quantitative fluorescence measurements that were below the threshold of the surgeon's visual perception were classified correctly in an analysis of all tumors. CONCLUSIONS: These findings are clinically profound because they demonstrate that ALA-induced PpIX is a targeting biomarker for a variety of intracranial tumors beyond HGGs. This study is the first to measure quantitative ALA-induced PpIX concentrations in vivo, and the results have broad implications for guidance during resection of intracranial tumors.
Authors: Pablo A Valdés; Xiaoyao Fan; Songbai Ji; Brent T Harris; Keith D Paulsen; David W Roberts Journal: Stereotact Funct Neurosurg Date: 2009-11-12 Impact factor: 1.875
Authors: David W Roberts; Jonathan D Olson; Linton T Evans; Kolbein K Kolste; Stephen C Kanick; Xiaoyao Fan; Jaime J Bravo; Brian C Wilson; Frederic Leblond; Mikael Marois; Keith D Paulsen Journal: J Neurosurg Date: 2017-08-04 Impact factor: 5.115
Authors: Kimberley S Samkoe; Summer L Gibbs-Strauss; Harold H Yang; S Khan Hekmatyar; P Jack Hoopes; Julia A O'Hara; Risto A Kauppinen; Brian W Pogue Journal: J Biomed Opt Date: 2011-09 Impact factor: 3.170
Authors: Mira Sibai; Israel Veilleux; Jonathan T Elliott; Frederic Leblond; Brian C Wilson Journal: Biomed Opt Express Date: 2015-11-19 Impact factor: 3.732
Authors: Eduardo H Moriyama; Weiguo Cao; Tracy W Liu; Han Lin Wang; Peter D Kim; Juan Chen; Gang Zheng; Brian C Wilson Journal: Mol Imaging Biol Date: 2014-08 Impact factor: 3.488
Authors: Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis Journal: J Neurooncol Date: 2021-02-21 Impact factor: 4.130
Authors: Johannes Knipps; Igor Fischer; Lisa M Neumann; Marion Rapp; Maxine Dibué-Adjei; Christiane Freiin von Saß; Jan-Malte Placke; Hendrik-Jan Mijderwijk; Hans-Jakob Steiger; Michael Sabel; Jan-Frederick Cornelius; Marcel A Kamp Journal: Clin Exp Metastasis Date: 2019-08-02 Impact factor: 5.150
Authors: Mira Sibai; Dennis J Wirth; Frederic Leblond; David W Roberts; Keith D Paulsen; Brian C Wilson Journal: J Biophotonics Date: 2019-03-20 Impact factor: 3.207